SCHEMBL24433804

SCHEMBL24433804

CC(C)(C)c1cc(O)ccc1Nc1ccc2cccc(C(C)(C)C)c2c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
CYP2C9 P11712 1/20 0.39
MIF P14174 1/20 0.39
TYR P14679 1/20 0.39
ALOX15 P16050 1/20 0.39
HTT P42858 1/20 0.39
NFE2L2 Q16236 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TRPV1 Q8NER1 10/20 0.39
MAPK14 Q16539 1/20 0.38
MCL1 Q07820 1/20 0.37
BRAF P15056 2/20 0.37
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
CDC25B P30305 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26522334 0.81 MCL1 (0.53) NR1I2ALDH1A1LMNACYP2C9MIF
SCHEMBL31590512 0.72 MAPT (0.43) ALDH1A1CYP2C9ALOX15HSD17B10BRAF
SCHEMBL11955002 0.71 ALDH1A1 (0.48) NR1I2ALDH1A1LMNACYP2C9MIF
SCHEMBL28838185 0.70 ALDH1A1 (0.52) ALDH1A1CYP2C9HSD17B10MAPK14MAPT
Hydroquinone SCHEMBL28095978 0.68 CA2 (0.45) NR1I2ALDH1A1LMNACYP2C9MIF
SCHEMBL11339706 0.67 ALDH1A1 (0.52) ALDH1A1LMNACYP2C9HTTHSD17B10
SCHEMBL10224686 0.67 MCL1 (0.49) TRPV1MCL1MAPT
SCHEMBL23074859 0.66 CYP2A6 (0.59) ALDH1A1TYRHSD17B10GAAMAPT
SCHEMBL19196145 0.66 CA2 (0.50) NR1I2ALDH1A1LMNACYP2C9MIF
SCHEMBL28423964 0.65 CA2 (0.46) NR1I2ALDH1A1LMNACYP2C9MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220155287-A1 SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS UNIV CALIFORNIA (US) 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220155287-A1 SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS SNCA, PARK7, SYNCRIP NR1I2 2568/4885ALDH1A1 3157/4885LMNA 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.